Table 1.
Parameters | Abs. f., (%) | |
---|---|---|
Age | < 35 | 7/89 (7.87) |
35-50 | 31/89 (34.83) | |
> 50 | 51/89 (57.3) | |
Menopause | No | 35/89 (39.33) |
Yes | 54/89 (60.67) | |
Tumor size | < 20 mm | 22/89 (24.72) |
20-50 mm | 62/89 (69.66) | |
> 50 mm | 5/89 (5.62) | |
Molecular type | Luminal A | 20/89 (22.47) |
Luminal B | 35/89 (39.33) | |
Triple-negative | 21/89 (23.6) | |
HER2-positive | 13/89 (14.6) | |
T | T1 | 25/89 (28.9) |
T2 | 46/89 (51.69) | |
T3 | 8/89 (8.99) | |
T4 | 10/89 (11.24) | |
N | N0 | 45/89 (50.56) |
N1 | 30/89 (33.71) | |
N2 | 10/89 (11.24) | |
N3 | 4/89 (4.49) | |
NACT | 37/89 (41.57) | |
Lymph node metastases | 39/89 (43.82) | |
ACT | 49/89 (55.06) | |
Chemotherapy regimen | Conventional | 29/89 (32.58) |
Conventional + Targeted | 5/89 (5.62) | |
Targeted | 8/89 (8.99) | |
Hormonal | 7/89 (7.87) | |
Grade | 2 | 77/89 (86.52) |
3 | 12/89 (13.48) | |
Frequency of distant metastases | 35/89 (39.33) |